Bristol-Myers Squibb: all 2,184 studies

Page 11 of 22. Open to participants first (162), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus ErythematosusActive, not recruitingNCT05620407Phase 3
• A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)Active, not recruitingNCT05617677Phase 3
• A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy ParticipantsCompletedNCT05615012Phase 1
• Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C MutationActive, not recruitingNCT05609578Phase 2
• A Post-Authorization, Long-term Study of Ozanimod Real-world SafetyActive, not recruitingNCT05605782
• A Study of Nivolumab, Ipilimumab, and Chemotherapy in Participants With Non-small Cell Lung CancerCompletedNCT05599685
• Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLCActive, not recruitingNCT05595460Phase 1
• A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female ParticipantsCompletedNCT05579574Phase 1
• A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK PathwayTerminatedNCT05578092Phase 1
• A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male ParticipantsCompletedNCT05567510Phase 1
• A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.Active, not recruitingNCT05567458Phase 2
• A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)Active, not recruitingNCT05552976Phase 3
• A Study to Assess Treatment Patterns, Clinical Outcomes and Healthcare Resource Utilization Among Adult Participants With Moderate-To-Severe Plaque PsoriasisCompletedNCT05547490
• A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese DescentCompletedNCT05546151Phase 1
• A Taste Assessment of Iberdomide and Mezigdomide in Healthy ParticipantsCompletedNCT05539976
• A Phase 1, First-in-Human Study of BMS-986421 in Healthy ParticipantsTerminatedNCT05517837Early Phase 1
• Study of Relatlimab in Combination With Nivolumab in Chinese ParticipantsCompletedNCT05498480Phase 1
• A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder CancerWithdrawnNCT05496192Phase 2
• Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyActive, not recruitingNCT05477576Phase 3
• A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)Active, not recruitingNCT05469737Phase 2/3
• A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of SulfasalazineCompletedNCT05445440Phase 1
• A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic TherapyCompletedNCT05432622
• Treatment Patterns and Outcomes in Participants With Advanced Melanoma in Germany Using a German DatabaseCompletedNCT05426239
• A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish DatabaseCompletedNCT05421442
• A Study to Assess 7/8 HLA-matched Hematopoietic Stem Cell Transplantation Participants Treated With or Without Abatacept in Combination With a Calcineurin Inhibitor and MethotrexateCompletedNCT05421299
• A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)CompletedNCT05420909
• A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) RegisterCompletedNCT05413044
• An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete RemissionActive, not recruitingNCT05413018Phase 2
• A Study to Evaluate the Drug Levels of BMS-986166 in Healthy Male ParticipantsCompletedNCT05409157Phase 1
• A Study to Evaluate the Safety, Tolerability, and Drug Levels of MYK-224 Administered in Single and Multiple Doses in Healthy Adult Japanese ParticipantsCompletedNCT05405543Phase 1
• A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy ParticipantsCompletedNCT05389722Phase 1
• A Study to Evaluate the Utilization, Effectiveness, and Quality of Life of Ozanimod in Participants With Ulcerative ColitisTerminatedNCT05382715
• A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy ParticipantsCompletedNCT05362045Phase 1
• A Study to Evaluate the Drug Exposure of Single Ascending Doses of BMS-986369 and the Effect of Food on the BMS-986369 in Healthy ParticipantsCompletedNCT05350800Phase 1
• A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy ParticipantsCompletedNCT05337345Phase 1
• A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)CompletedNCT05335031
• A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreated Advanced/Recurrent Gastric CancerCompletedNCT05334719
• A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)CompletedNCT05324436
• A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy ParticipantsCompletedNCT05320094Phase 1
• An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaCompletedNCT05304767Phase 3
• A Study to Assess the Drug Interaction Between MYK-224 and Itraconazole and Verapamil in Healthy ParticipantsCompletedNCT05304533Phase 1
• A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy ParticipantsCompletedNCT05303220Phase 1
• Expanded Access for Bromodomain and Extra-Terminal (BET) InhibitorNo longer availableNCT05301972
• A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced TumorsCompletedNCT05298592Phase 1
• A Study to Evaluate the Drug Levels of [14C]CC-99677 in Healthy Male ParticipantsCompletedNCT05284890Phase 1
• PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.CompletedNCT05255276Phase 1
• A Study of Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung CancerCompletedNCT05250817
• A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT05244070Phase 1
• A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed ConditionsCompletedNCT05236738Phase 1
• A Study Evaluating the Associations Between Clinical Characteristics and Use of Oral Anticoagulants in Italian Elderly Participants With Non-Valvular Atrial FibrillationCompletedNCT05232643
• A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)CompletedNCT05218902
• A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class ExposureCompletedNCT05217082
• Expanded Access for Anti-IL8No longer availableNCT05210894
• A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid MalignanciesTerminatedNCT05209295Phase 1
• Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)CompletedNCT05178888Phase 1
• A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving CendakimabCompletedNCT05175352Phase 1
• Expanded Access for Fixed-Dose Combination of Nivolumab Plus RelatlimabNo longer availableNCT05170685
• Expanded Access for AbataceptNo longer availableNCT05170672
• Expanded Access for RelatlimabNo longer availableNCT05170659
• A Study of Preferences of Participants and Oncologists for the Characteristics of the Treatment for Renal Cell Carcinoma (RCC) In Spain And PortugalCompletedNCT05168436
• A Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric CancerActive, not recruitingNCT05165264
• Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C MutationApproved for marketingNCT05162443
• A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-dose of Danicamtiv in Healthy ParticipantsCompletedNCT05162222Phase 1
• A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in JapanActive, not recruitingNCT05161325
• A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese ParticipantsCompletedNCT05136677Phase 2
• A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid TumorsCompletedNCT05134948Phase 1/2
• A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Participants in EuropeCompletedNCT05123950
• A Study of Adjuvant Melanoma Stakeholder Treatment PreferencesCompletedNCT05115006
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult ParticipantsTerminatedNCT05099822Phase 1
• A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)CompletedNCT05068609
• Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice ExperimentCompletedNCT05065762
• Positron Emission Tomography (PET) Imaging Study to Evaluate Enzyme Availability in the Central Nervous System Before and After CC-97489 Administration in Healthy ParticipantsCompletedNCT05065541Phase 1
• A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult ParticipantsCompletedNCT05051553Phase 1
• A Study Evaluating Quality of Life for Participants With Atrial Fibrillation (AF) Following a Bleed (EQUAL-AF)CompletedNCT05044533
• A Study of Nivolumab in Participants With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and CyprusCompletedNCT05034926
• A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in JapanCompletedNCT05027061
• Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid TumorsCompletedNCT05001516Phase 1
• Taste Assessment of OzanimodCompletedNCT05001152Phase 1
• Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort StudyTerminatedNCT04982471
• Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult ParticipantsCompletedNCT04978298Phase 1
• Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Active, not recruitingNCT04975997Phase 3
• Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple MyelomaTerminatedNCT04975399Phase 1
• Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)TerminatedNCT04975256Phase 1
• Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs)CompletedNCT04973280
• A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986166 in Healthy Japanese ParticipantsCompletedNCT04965402Phase 1
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-99677 in Healthy Adult Japanese Participants.CompletedNCT04958291Phase 1
• A Study to Assess the Effect of Itraconazole, Phenytoin and Gemfibrozil on the Drug Levels of BMS-986166 in Healthy ParticipantsCompletedNCT04956627Phase 1
• Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic SyndromesTerminatedNCT04951778Phase 1
• A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy ParticipantsCompletedNCT04949269Phase 1
• A Study of BMS-986416 With and Without Nivolumab in Select Solid TumorsCompletedNCT04943900Phase 1
• A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy ParticipantsCompletedNCT04941755Phase 1
• A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United KingdomCompletedNCT04936399
• A Study to Explore the Effect of Acid-reducing AgentsCompletedNCT04935112Phase 1
• A Study to Characterize the Drug Levels of an Oral Contraceptive With and Without BMS-986166 in Healthy Female Participants of Childbearing PotentialCompletedNCT04934696Phase 1
• Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney FunctionCompletedNCT04933747Phase 1
• A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 AbsorptionCompletedNCT04926051Phase 1
• A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)CompletedNCT04887857Phase 1
• PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of SubstratesCompletedNCT04887194Phase 1
• Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat LymphomaActive, not recruitingNCT04884035Phase 1
• Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell LymphomaWithdrawnNCT04882163Phase 1/2

← Bristol-Myers Squibb overview and focus areas